For PRODUCT INFORMATION {Click Here}
News Room

Press Releases

 

11/18/2013
New Clinical Trial to Study Use of MYOBLOC® Injections into Salivary Glands to Treat Sialorrhea

10/10/2013
US WorldMeds Receives 2013 Kentucky Excellence Award

8/7/2013
Omnicare Specialty Care Group's ACS to Provide Specialty Pharmacy Services for APOKYN®

6/18/2013
US WorldMeds Receives $15 Million Grant to Launch New Study

5/13/2013
New clinical trial investigates APOKYN for treating debilitating morning akinesia in PD patients

4/27/2013
US WorldMeds co-sponsors the 2013 Parkinson's Unity Walk

3/26/2013
Eisai to Launch Botulinum Toxin Type B Neuromuscular-Blocking Agent Nerbloc® Intramuscular Injection 2500 Units in Japan

9/2/2011
US WorldMeds Implements a Co-Pay Assistance Program for Patients Using MYOBLOC®

7/01/2011
Revonto® Saves Lives in Armenia

3/15/2011
Revonto® arrives in Tanzania and El Salvador

2/24/2011
US WorldMeds Receives $3 Million from NIDA to Develop Drug That Relieves
Withdrawal Symptoms in Opiate Dependent Patients

2/02/2011
US WorldMeds Announces Launch of ALSUMA™ (sumatriptan injection) 6 mg/0.5 mL Auto-Injector

8/13/2010
US WorldMeds Acquires Solstice Neurosciences

6/16/2010
US WorldMeds, LLC joins National Association of Chain Drug Stores (NACDS)

5/26/2010
US WorldMeds, LLC joins Healthcare Management Distribution Association (HDMA)

4/26/2010
Glenn Esgro joins US WorldMeds, LLC

1/11/2010
US WorldMeds receives FDA approval for the proprietary name, Revonto™

11/12/2009
US WorldMeds is Named 2009 Hot Dozen Company

5/28/2009
US WorldMeds receives FDA approval for its enhanced reconstituting product, Revonto™

5/01/2009
US WorldMeds and Nursing CE Portal Team Up

6/16/2008
US WorldMeds Completes Phase III Trial of Lofexidine for Treatment of Opiate Withdrawal Symptoms

5/05/2008
US WorldMeds Completes Development of Instantaneous Reconstitution Dantrolene Sodium for Injection Product.